Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
From Jan 2020: how each company's value moved, whatever its size.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Codexis, Inc.✕ CDXS · #17,521 in the world | CSL Limited✕ CSL.AX · #490 in the world | Moderna, Inc.✕ MRNA · #275 in the world |
|---|---|---|---|
| Profile | |||
| Country | 🇺🇸 USA | 🇦🇺 Australia | 🇺🇸 USA |
| Sector | Healthcare | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology | Biotechnology |
| Founded | 2002 | 1916 | 2010 |
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Codexis, Inc. | CSL Limited | Moderna, Inc. |
|---|---|---|---|
| 2025 | $70 MSEC | — | $1.9 BSEC |
| 2024 | $59 MSEC | — | $3.2 BSEC |
| 2023 | $70 MSEC | — | $6.8 BSEC |
| 2022 | $139 MSEC | — | $19.3 BSEC |
| 2021 | $105 MSEC | — | $18.5 BSEC |
| 2020 | $69 MSEC | — | $803 MSEC |
| 2019 | $68 MSEC | — | $60 MSEC |
| 2018 | $61 MSEC | — | $135 MSEC |
| 2017 | $50 MSEC | — | $206 MSEC |
| 2016 | $49 MSEC | — | $108 MWD |
| 2015 | $42 MSEC | — | — |
| 2014 | $35 MSEC | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| Size | |||
|---|---|---|---|
| Market cap | $140 M | $51.6 B | $90.1 B |
| Revenue | $70 M | $15.7 B | $1.9 B |
| Net income | $-44 M▲ best | $-2.6 B | $-2.8 B |
| Employees | 261 | 30,000 | 4,700 |
| Valuation | |||
|---|---|---|---|
| Price to sales | 1.6× | 3.3× | 35.7× |
| Price to book | 2.8× | 3.2× | 10.4× |
| Free cash flow yield | -17.0% | — | -2.3%▲ best |
| Profitability | |||
|---|---|---|---|
| Gross margin | 86.7%▲ best | — | 55.4% |
| Operating margin | -59.3%▲ best | — | -158.1% |
| Net margin | -62.5%▲ best | — | -145.2% |
| Return on equity | -74.9% | — | -28.9%▲ best |
| Growth | |||
|---|---|---|---|
| Revenue growth | 18.6%▲ best | — | -39.9% |
| Revenue growth, 3 years a year | -20.2%▲ best | — | -53.4% |
| Financial strength | |||
|---|---|---|---|
| Debt to equity | 0.8× | — | 0.1×▲ best |
| Cash | |||
|---|---|---|---|
| Free cash flow margin | -33.9%▲ best | — | -106.2% |
| Shareholder returns | |||
|---|---|---|---|
| Shareholder yield | — | — | 0.0% |
| Strength scores | |||
|---|---|---|---|
| Piotroski F-score | 4 of 9▲ best | — | 3 of 9 |
| Altman Z-score zone | distress | — | safe |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Aug 2026 | Market cap Oct 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.